

Fee Schedule Change for Certain A, J, and Q Code Drugs

Effective **Jan. 1, 2022**, we will update participating physician fee schedules for certain A, J, and Q code drugs. The fee schedule changes will affect the majority of participating physicians who administer these drugs.

Drugs Affected by This Change

The fee schedule changes are effective for claims with a date of service on or after Jan. 1, 2022, for the drugs listed in the table below.

HCPCS	Drug Description	HCPCS	Drug Description
A9513	Lutetium Lu 177 dotatate [LUTATHERA]	J9042	Brentuximab vedotin [ADCETRIS]
J0640	Leucovorin calcium [LEUCOVORIN]	J9177	Enfortumab vedotin [PADCEV]
J1439	Ferric carboxymaltose [INJECTAFER]	J9228	Ipilimumab [YERVOY]
J1454	Fosnetupitant-palonosetron [AKYNZEO]	J9267	Paclitaxel [TAXOL]
J1554	Immune globulin [ASCENIV]	J9271	Pembrolizumab [KEYTRUDA]
J1627	Granisetron, extended-release [SUSTOL]	J9299	Nivolumab [OPDIVO]
J2350	Ocrelizumab [OCREVUS]	J9318	Romidepsin, non-lyophilized
J7314	Fluocinolone acetonide implant [YUTIQ]	J9319	Romidepsin, lyophilized [ISTODAX]
J7351	Bimatoprost implant [DURYSTA]	Q2043	Sipuleucel-T [PROVENGE]

Process for Preservice Reviews

There is no change to the process for requesting a preservice medical necessity review for A, J, and Q code drugs. Please continue to contact Magellan Rx Management as you do today through their secure website at <https://magellanrx.com> or by calling them at 800-424-4947.

More Information

To determine if this change affects you, please refer to your physician fee schedule.